What exactly is the Technosphere® Platform?

NTM Lung Disease on the Rise

Our therapeutic innovations are empowering people to live life – fully human.

MannKind Corporation is focused on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

Download our MNKD Corporate Presentation

We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease.

Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.

With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

 

Featured Links

Minimum 15 minutes delayed. Source:

view more stock info

investor FAQs

Show All
  • When was MannKind Corporation founded?

    February 1991

  • What is your fiscal year?

    December 31

  • On which exchange does MannKind trade and what is the symbol?

    Nasdaq: MNKD

  • How do I contact your Investor Relations?

    Please email ir@mnkd.com

  • Where is MannKind located?

    1 Casper Street
    Danbury, CT 06810
     
    30930 Russell Ranch Road, Suite 300
    Westlake Village, CA 91362
     
    293 Boston Post Road West #330
    Marlborough, MA 01752

  • Who is your transfer agent?

    Computershare


    Mailing Address:
    P.O. Box 43006
    Providence RI 02940-3006

    Courier Delivery:
    150 Royal St., Suite 101
    Canton, MA 02021

email alerts

You may automatically receive MannKind Corporation information by email. Please enter your email address and provide your email preference selections. Confirm you are not a robot and click submit.